Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Sha Klabunde"'
Autor:
Nicholas S. Jones, Smita Kshirsagar, Vishnu Mohanan, Vidya Ramakrishnan, Flavia Di Nucci, Ling Ma, Jialin Mao, Hao Ding, Sha Klabunde, Domagoj Vucic, Lin Pan, Annemarie N. Lekkerkerker, Yuan Chen, Michael E. Rothenberg
Publikováno v:
Clinical and Translational Science, Vol 16, Iss 10, Pp 1997-2009 (2023)
Abstract Receptor‐interacting protein 1 (RIP1) is a key regulator of multiple signaling pathways that mediate inflammatory responses and cell death. RIP1 kinase activity mediates apoptosis and necroptosis induced by tumor necrosis factor (TNF)‐α
Externí odkaz:
https://doaj.org/article/d142bcfea4d8440d95ab3f753b2b144b
Autor:
Charlotte Lichnog, Sha Klabunde, Emily Becker, Franklin Fuh, Philipp Tripal, Raja Atreya, Entcho Klenske, Rich Erickson, Henry Chiu, Chae Reed, Shan Chung, Clemens Neufert, Imke Atreya, Jacqueline McBride, Markus F. Neurath, Sebastian Zundler
Publikováno v:
Frontiers in Pharmacology, Vol 10 (2019)
Background: Anti-integrin therapy is a new frontline strategy in the treatment of inflammatory bowel diseases (IBD). The anti-β7 integrin antibody etrolizumab is currently being investigated for safety and efficacy in Crohn’s disease (CD) and ulce
Externí odkaz:
https://doaj.org/article/f1a7cedb62f746388bc1be550968ff7b
Autor:
Lucinda Tam, Annemarie Lekkerkerker, Jeffrey Eastham-Anderson, Melanie Domeyer, Brent S. McKenzie, Azadeh Hadadianpour, Eugene Varfolomeev, Arna Katewa, Steven Do, A. Francesca Setiadi, Wyne P. Lee, Joy Drobnick, Andres Paler-Martinez, Rajita Pappu, Katherine Bao, Marian C. Bryan, Alfred Wong, James J. Crawford, Cesar A. Corzo, Vida Asghari, Sha Klabunde, Vladimir Ramirez-Carrozi, Jodie Pang, Jason A. Hackney, Hans Brightbill, Christopher Dela Cruz, Ross Francis, Yonglian Sun, Merone Roose-Girma, Claire Emson, Wendy B. Young, Michael J. Townsend, James R. Kiefer, Cary D. Austin, Swathi Sujatha-Bhaskar, Emily Hunley, Nico Ghilardi, Daqi Xu, Søren Warming, Kate Senger, Zhiyu Huang, Vivian W. C. Lau, Domagoj Vucic, Ali A. Zarrin, Eric Suto
Publikováno v:
Science signaling. 13(634)
The dysregulation of multiple signaling pathways, including those through endosomal Toll-like receptors (TLRs), Fc gamma receptors (FcγR), and antigen receptors in B cells (BCR), promote an autoinflammatory loop in systemic lupus erythematosus (SLE)
Autor:
Charlotte Lichnog, Sha Klabunde, Emily Becker, Franklin Fuh, Philipp Tripal, Raja Atreya, Entcho Klenske, Rich Erickson, Henry Chiu, Chae Reed, Shan Chung, Clemens Neufert, Imke Atreya, Jacqueline McBride, Markus F. Neurath, Sebastian Zundler
Publikováno v:
Frontiers in Pharmacology
Frontiers in Pharmacology, Vol 10 (2019)
Frontiers in Pharmacology, Vol 10 (2019)
Background: Anti-integrin therapy is a new frontline strategy in the treatment of inflammatory bowel diseases (IBD). The anti-β7 integrin antibody etrolizumab is currently being investigated for safety and efficacy in Crohn’s disease (CD) and ulce
Autor:
Anu Cherukuri, Wen-Kai Weng, Georgios V. Georgakis, Mohammad Luqman, Edward E. Kadel, Jocelyn Holash, Sharon Lea Aukerman, Cheryl Goldbeck, Sang Hoon Lee, Karen Lin, Anas Younes, Natasha Aziz, Bahija Jallal, Sha Klabunde, Susan O'Brien, Xiaomei Xu, William G. Wierda
B-cell chronic lymphocytic leukemia (B-CLL) is a lymphoproliferative disorder characterized by the surface expression of CD20, CD5 antigens, as well as the receptor CD40. Activation of CD40 by its ligand (CD40L) induces proliferation and rescues the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0840749fbef67b2210961517a4b75df2
https://europepmc.org/articles/PMC2481542/
https://europepmc.org/articles/PMC2481542/
Autor:
Caroline Looney, Sha Klabunde, Clarissa F. Johnson, Franklin Fuh, William R. Mathews, Dimitry M. Danilenko, Kathleen Howell, Marna Williams, Sharon O'Byrne
Publikováno v:
Gastroenterology. 142:S-383
Publikováno v:
Blood. 110:528-528
HCD122 (formerly known as CHIR-12.12), is a fully human anti-CD40 monoclonal antibody (mAb) currently in Phase I clinical trials for treatment of chronic lymphocytic leukemia (CLL) and multiple myeloma (MM). An IgG1 antibody selected for its potency